Ipsen (FRA:I7G) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:I7G Ipsen SA FRA:I7G
97 GF Score
Price €154.00
GF Value €140.64
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Ipsen Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

FRA:I7G
97GF Score
Ipsen SA FRA:I7G
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ipsen (FRA:I7G) Overvalued in 2026?

Based on GuruFocus' analysis, Ipsen stock appears to be overvalued. The current stock price of €154.00 is trading 9.5% above its estimated GF Value™ of €140.64. GuruFocus considers Ipsen to be Fairly Valued.

Key valuation signals for FRA:I7G:

  • Dividends Received:
  • GF Value™: €140.64 vs. price of €154.00 (9.5% above fair value)
  • GF Score™: 97/100 with 6 warning signs

No single metric tells the full story. See the FRA:I7G stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ipsen Business Description

Address 70 rue Balard, Paris, FRA, 75015
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders, but in February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for only 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 20 drugs in 115 countries.
97GF Score

Get the complete analysis for FRA:I7G

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€154.00
Price
€140.64
GF Value